Jul 2026· Journal of Genetic Engineering and Biotechnology· Vol 24· 0 citations· 36 references
TL;DR
This study generated a novel recombinant AAV vector rAAV.hu.hu.S17, derived from the human spleen isolate AAV.hu.S17, and systematically evaluated its capsid features, in vitro transduction, and in vivo tissue tropism.
Abstract
Adeno-associated viruses (AAVs) are widely used vectors for gene therapy owing to their nonpathogenic nature, low immunogenicity, and ability to support long-term transgene expression. However, the tissue tropism and immune response of AAVs are strongly dependent on their capsid serotype. Although hundreds of naturally occurring AAV variants have been isolated, many remain unvectorised and poorly characterized. Therefore, the discovery and development of previously uncharacterised native serotypes retain valuable. Here, we generated a novel recombinant AAV vector rAAV.hu.S17, derived from the human spleen isolate AAV.hu.S17, and systematically evaluated its capsid features, in vitro transduction, and in vivo tissue tropism. Sequence analysis showed that AAV.hu.S17 is closely related to AAV2 and AAV3, and shares 90.9% amino acid identity to AAV2 across the capsid proteins. High-titer vector production was achieved using the triple-plasmid system, with rAAV.hu.S17 yielding approximately 2.68-fold more vector than that of rAAV2. Although rAAV.hu.S17 showed ∼20-fold lower transduction in HEK293T cells than rAAV2 in vitro, it mediated higher neuronal transduction in the mouse primary visual cortex (V1) in vivo. Following intravitreal injection into C57BL/6 mice, rAAV.hu.S17 preferentially transduced photoreceptors in the outer nuclear layer (ONL), with minimal transduction of the inner nuclear layer (INL) and the ganglion cell layer (GCL). Collectively, these results demonstrate that rAAV.hu.S17 exhibits transduction characteristics distinct from those of rAAV2 in both the brain and retina. This study provides the first vectorization and biological characterization of the previously uncharacterized human AAV isolate AAV.hu.S17 and expands the repertoire of naturally occurring AAV capsids available for future biological investigation and vector engineering.
The results showed the potential of a combinatorial AAV library for model validation and revealed the human microliver platform-PEG as a reliable system for the development of AAV therapeutics.
Carmen Unzu, Amanda X. Chen, Liliana Mancio-Silva et al.· bioRxiv· 0 citations
The data support the genomic safety of rAAV6 and its applicability to hematological gene therapy and functional enrichment analysis indicated associations with general cellular and structural processes, without enrichment in oncogenic pathways.
H. Lee, Nayoung Park, In-Byung Park et al.· International Journal of Ste...· 0 citations
Recovery of adeno-associated virus (AAV) vectors from culture supernatants has attracted increasing interest as a strategy to simplify downstream processing and improve product purity. However, several AAV serotypes can be re-internalized by producer cells, raising the possibility that newly released particles are recaptured during production and thereby limiting extracellular yield. Because AAV entry is mediated by the universal receptor KIAA0319L (AAVR), receptor-dependent re-uptake may contribute to this limitation, yet its role in vector manufacturing remains unexplored. Here, we investigated whether disruption of AAVR enhances supernatant-based AAV recovery. Using CRISPR-Cas9-mediated genome editing, we generated AAVR-knockout (AAVR-KO) HEK293-EB producer cells by deleting exon 2 containing the translational start codon. AAVR ablation abolished susceptibility to multiple AAV serotypes and markedly reduced cellular uptake of extracellular particles. In supernatant AAV vector recovery assays, AAVR knockout increased supernatant vector genome recovery for selected serotypes in a representative clone, although this effect varied among independently isolated clones. Complementary AAVR overexpression reduced accumulation of extracellular AAV1 vector genomes, supporting a role for AAVR expression levels in supernatant recovery while also suggesting additional effects on production-related cellular processes. These findings identify AAVR-dependent cellular uptake or retention as a modifiable post-release process that can influence supernatant-based AAV vector recovery.
A novel approach to detarget liver transduction is developed by transiently downregulating the expression of key entry factors in this tissue using GalNac-siRNAs prior to AAV9 administration, which blunted hepatic transduction but also redirected the vector to other transduction-permissive tissues.
Katie Kubek-Luck, J. Velazquez, Xiao-Rui Yao et al.· Molecular Therapy· 0 citations